We see concentrated drug sourcing persisting in 2024, leading to continuous shortages on a global scale. Over-reliance on India and China for vital pharmaceutical ingredients heightens risks during regional disruptions, creating widespread supply challenges for governments worldwide. Policy shifts are anticipated in the US and Europe to reduce dependence on specific manufacturing hubs. These initiatives aim to tackle scarcity issues and mitigate inflated costs, particularly impacting generic drugmakers operating in the market. With these vulnerabilities in global supply chains, diversified sourcing becomes imperative. Pharma Contract Partners is ready to assist in navigating these challenges, ensuring stable supplies and cost-effective solutions for your most valuable asset. Stay #protected in 2024! #PharmaSupplyChain #DrugSourcing
关于我们
With over 25+ years of market intelligence and benchmarking, Pharma Contract Partners facilitates cost savings in the drug development process by ensuring that chemists, scientists, clinicians, and engineers are protected from overspending.
- 网站
-
https://pharmacpartners.com/
Pharma Contract Partners的外部链接
- 所属行业
- 制药业
- 规模
- 11-50 人
- 总部
- Philadelphia
- 类型
- 私人持股
地点
-
主要
获取路线
US，Philadelphia